您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Moexipril-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Moexipril-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Moexipril-d5图片
CAS NO:1356929-49-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
An internal standard for the quantification of moexipril
Cas No.1356929-49-1
Canonical SMILES[2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1CC[C@@H](C(OCC)=O)N[C@@H](C)C(N2CC3=CC(OC)=C(OC)C=C3C[C@H]2C(O)=O)=O
分子式C27H29D5N2O7
分子量503.6
溶解度DMSO: soluble,Methanol: soluble
储存条件-20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Moexipril-d5intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat.1It is converted to moexiprilatin vivoby side chain ester hydrolysis.2Moexipril inhibits ACE in a cell-free assay (IC50= 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively).2Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.3

1.Edling, O., Bao, G., Feelisch, M., et al.Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalaprilJ. Pharmacol. Exp. Ther.275(2)854-863(1995) 2.Cameron, R.T., Coleman, R.G., Day, J.P., et al.Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Biochem. Pharmacol.85(9)1297-1305(2013) 3.Ravati, A., Junker, V., Kouklei, M., et al.Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and ratsEur. J. Pharmacol.373(1)21-33(1999)